Selected article for: "early stage and inflammatory storm"

Author: Hirawat, Rishabh; Saifi, Mohd Aslam; Godugu, Chandraiah
Title: Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications
  • Cord-id: wnec7s05
  • Document date: 2021_2_15
  • ID: wnec7s05
    Snippet: Such testing and trying time probably never seen before in the human history. The novel coronavirus disease abbreviated as COVID-19 is the ongoing health crisis which entered into human life in late December 2019. The ease of transmission between humans and the undetectability in early stage makes COVID-19 frightening and unprecedented. The disease is characterised by pneumonia progressing to breathing difficulty, acute respiratory distress syndrome (ARDS) and multi-organ failure. Clinical studi
    Document: Such testing and trying time probably never seen before in the human history. The novel coronavirus disease abbreviated as COVID-19 is the ongoing health crisis which entered into human life in late December 2019. The ease of transmission between humans and the undetectability in early stage makes COVID-19 frightening and unprecedented. The disease is characterised by pneumonia progressing to breathing difficulty, acute respiratory distress syndrome (ARDS) and multi-organ failure. Clinical studies suggest excessive release of inflammatory mediators leads to cytokine storm, a phenomenon which appears to be potentially life-threatening in COVID-19. Across the globe, when the world authorities are grappling to contain the virus, our review provides a glimpse on structure, pathophysiology of the virus and further sheds light on various clinical complications associated with the disease in order to open up/raise new horizons to explore various possible theoretical targets for COVID-19. The review also portrays a question and debates: Can targeting cytokine storm can be a feasible approach to combat COVID-19?

    Search related documents:
    Co phrase search for related documents
    • aberrant release and adaptive immunity: 1
    • aberrant release and macrophage activation: 1
    • aberrant release and macrophage activation syndrome: 1
    • acetic acid and acid production: 1, 2, 3, 4, 5
    • acetic acid and acute injury: 1
    • acetic acid and acute lung injury: 1
    • acetic acid and liver injury: 1
    • acetic acid and lps expression: 1, 2
    • acetic acid and lung damage: 1
    • acetic acid and lung injury: 1
    • acetic acid and lung tissue: 1